Innovita Biological Technology Co., Ltd. (SHA:688253)
China · Delayed Price · Currency is CNY 44.68
-0.13 (-0.29%)
At close: Apr 21, 2026
SHA:688253 Revenue
In the year 2025, Innovita Biological Technology had annual revenue of 422.03M CNY, down -32.08%. Innovita Biological Technology had revenue of 91.63M in the quarter ending December 31, 2025, a decrease of -8.88%.
Revenue
422.03M
Revenue Growth
-32.08%
P/S Ratio
14.28
Revenue / Employee
771.54K
Employees
558
Market Cap
6.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 422.03M | -199.36M | -32.08% |
| Dec 31, 2024 | 621.39M | 143.37M | 29.99% |
| Dec 31, 2023 | 478.02M | 31.40M | 7.03% |
| Dec 31, 2022 | 446.62M | 119.71M | 36.62% |
| Dec 31, 2021 | 326.91M | -710.19M | -68.48% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.26B |
| Wuhan Hvsen Biotechnology | 1.68B |
| Kexing Biopharm | 1.54B |
| Shenzhen Weiguang Biological Products | 1.14B |
| ChemPartner PharmaTech | 1.07B |
| Beijing Konruns Pharmaceutical | 871.31M |
| R&G PharmaStudies | 851.01M |
| PharmaResources (Shanghai) | 667.47M |